Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | The real-world outcomes of patients with CLL who discontinue BTKi therapy

Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses the findings of the observational GIMEMA CLL2121 study (NCT04867915), which investigated the real-world outcomes of patients with chronic lymphocytic leukemia (CLL) who discontinued BTK inhibitor (BTKi) treatment. The treatment discontinuation rate was higher in the real-world setting than that reported in clinical trials. Almost one-third of patients discontinued therapy due to disease progression, and the outcomes of these patients were poorer than those patients who discontinued BTKi therapy due to intolerance. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.